Showing 4481-4490 of 8095 results for "".
- The Aeshetic Show: Organizers Highlight Top Reasons to Attendhttps://practicaldermatology.com/news/the-aeshetic-show-organizers-highlight-top-reasons-to-attend/2461244/Unique in its multidisciplinary approach, The Aesthetic Show has, for more that 15 years, covered the rapidly-expanding field of aesthetic medicine. Attendees can unite with contemporaries across various medical disciplines, learn trailblazing techniques, and discover the groundbreaking solutions
- Senté Launches Even Tone Mineral Sunscreenhttps://practicaldermatology.com/news/sente-launches-even-tone-mineral-sunscreen/2461230/Senté has launched Even Tone Mineral Sunscreen. The new tinted sunscreen formulas protect the skin from damage caused by visible light in addition to UV rays and are specifically designed to promote even skin tone in every complexion, the company says.
- And the Winners Are...Newsweek Names America’s Top Dermatologistshttps://practicaldermatology.com/news/and-the-winners-arenewsweek-names-americas-top-dermatologists/2461226/Newsweek has released the 2022 America‘s Best Dermatologists List in partnership with Statista. The list is split into two categories: cosmetic and medical and includes 275 dermatologists (125 cosmetic and 150 medical), many of whom sit on Practical Dermatology® and sister pub
- Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trialshttps://practicaldermatology.com/news/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lillys-lebrikizumab-atopic-dermatitis-monotherapy-trials/2461223/Fully 80 percent of lebrikizumab responders maintained improvements in skin clearance and atopic dermatitis disease severity at 52 weeks with once every two week and once every four week maintenance dosing, according to topline results from the Phase 3 clinical trials (ADvocate 1 a
- Timber's Topical Isotretinoin Gets Breakthrough Therapy Designation for CIhttps://practicaldermatology.com/news/timbers-topical-isotretinoin-gets-breakthrough-therapy-designation-for-ci/2461217/TMB-001, a topical isotretinoin formulated using patented IPEG™ delivery system from Timber Pharmaceuticals, Inc. has been granted Breakthrough Therapy designation by FDA for the treatment of congenital ichthyosis (CI). Timber is developi
- Amytrx Therapeutics Raises $18M for New AD Treatmenthttps://practicaldermatology.com/news/amytrx-therapeutics-raises-18m-for-new-ad-treatment/2461211/Amytrx Therapeutics closed on its final tranche of its Series A capital raise, totaling $18 million to expand on its clinical research investigating AMTX-100, a new cell- penetrating immune system modulating peptide therapeutic for topical skin applications, specifically in atopic derma
- Study: All Moisturizer Types Equally Effectivehttps://practicaldermatology.com/news/study-all-moisturizer-types-equally-effective/2461209/No one type of moisturizer is better than another, according to the Best Emollients for Eczema trial. This study, the first to directly compare different types of moisturizers, highlights the importance of patient education and choice when deciding which moisturizers to use for children
- Three Beliefs Affect Older Adults Sunscreen Usehttps://practicaldermatology.com/news/three-beliefs-affect-older-adults-sunscreen-use/2461202/Reminders from a romantic partner might be an effective way to encourage sunscreen use by people age 50 or older, suggests a study in the May/June issue of The Journal of the Dermatology Nurses' Association. People older than 50 are also more likely to use su
- Almirall and Inserm Transfert Collaborate to Develop Innovative Treatments for Vitiligohttps://practicaldermatology.com/news/almirall-and-inserm-transfert-collaborate-to-develop-innovative-treatments-for-vitiligo/2461198/Almirall, S.A. and Inserm Transfert, the private subsidiary of the French National Institute of Health and Medical Research (Inserm), have entered into a licensing agreement and research collaboration to advance treatment options for vitiligo. The partnership, signed by
- New Two-Year Data on Deucravacitinib Reinforce Efficacy and Safety Profile in Treatment of Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/new-two-year-on-bms-deucravacitinib-data-reinforce-efficacy-and-safety-profile-in-treatment-of-moderate-to-severe-plaque-psoriasis/2461191/Bristol Myers Squibb shared new two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating durable efficacy and a consistent safety profile with deucravacitinib treatment in adult patients with moderate to severe plaque psoriasis. Clinical efficacy was maintained through u